Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
Cantor Fitzgerald
Cipla
Harvard Business School
Citi
Merck
Teva
Mallinckrodt
Argus Health
Boehringer Ingelheim

Generated: October 17, 2017

DrugPatentWatch Database Preview

NOVARTIS PHARMS CORP Company Profile

« Back to Dashboard

What is the competitive landscape for NOVARTIS PHARMS CORP, and when can generic versions of NOVARTIS PHARMS CORP drugs launch?

NOVARTIS PHARMS CORP has sixty-eight approved drugs.

There are one hundred and nineteen US patents protecting NOVARTIS PHARMS CORP drugs and there have been six Paragraph IV challenges on NOVARTIS PHARMS CORP drugs in the past three years.

There are one thousand eight hundred and nineteen patent family members on NOVARTIS PHARMS CORP drugs in seventy-two countries and one hundred and sixty supplementary protection certificates in fifteen countries.

Summary for Applicant: NOVARTIS PHARMS CORP

International Patents:1819
US Patents:119
Tradenames:58
Ingredients:49
NDAs:68
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
ALCAINE
proparacaine hydrochloride
SOLUTION/DROPS;OPHTHALMIC080027-001Approved Prior to Jan 1, 1982ATRXNoYes► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
FARYDAK
panobinostat lactate
CAPSULE;ORAL205353-001Feb 23, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
PROMACTA
eltrombopag olamine
TABLET;ORAL022291-004Oct 20, 2011RXYesNo► Subscribe► SubscribeY► Subscribe
Novartis Pharms Corp
MEKINIST
trametinib dimethyl sulfoxide
TABLET;ORAL204114-002May 29, 2013DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
ZOFRAN ODT
ondansetron
TABLET, ORALLY DISINTEGRATING;ORAL020781-001Jan 27, 1999ABRXYesNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
FARYDAK
panobinostat lactate
CAPSULE;ORAL205353-002Feb 23, 2015RXYesNo► Subscribe► Subscribe ► Subscribe
Novartis Pharms Corp
JADENU
deferasirox
TABLET;ORAL206910-002Mar 30, 2015RXYesNo► Subscribe► SubscribeY ► Subscribe
Novartis Pharms Corp
KISQALI FEMARA CO-PACK (COPACKAGED)
letrozole; ribociclib succinate
TABLET, TABLET;ORAL209935-001May 4, 2017RXYesYes► Subscribe► SubscribeYY ► Subscribe
Novartis Pharms Corp
MEKINIST
trametinib dimethyl sulfoxide
TABLET;ORAL204114-001May 29, 2013RXYesNo► Subscribe► Subscribe► Subscribe
Novartis Pharms Corp
FARYDAK
panobinostat lactate
CAPSULE;ORAL205353-003Feb 23, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Novartis Pharms Corp

Paragraph IV activity for NOVARTIS PHARMS CORP drugs

Drugname Dosage Strength Tradename Submissiondate
deferasirox
Tablets180 mg
JADENU
4/28/2016
travoprost
Ophthalmic Solution0.003%
IZBA
12/30/2015
nepafenac
Ophthalmic Suspension0.3%
ILEVRO
12/21/2015
deferasirox
Tablets180 mg
JADENU
10/23/2015
deferasirox
Tablets90 mg and 360 mg
JADENU
10/19/2015
olopatadine hydrochloride
Ophthalmic Solution0.7%
PAZEO
9/10/2015
difluprednate
Ophthalmic Emulsion0.05%
DUREZOL
5/1/2014
eltrombopag olamine
Tablets12.5 mg and 25 mg
PROMACTA
2/4/2014
eltrombopag olamine
Tablets50 mg and 75 mg
PROMACTA
1/7/2014
ciprofloxacin and dexamethasone
Otic Suspension0.3%/0.1%
CIPRODEX
7/31/2012
moxifloxacin hydrochloride
Ophthalmic Solution10.5%
MOXEZA
2/29/2012
argatroban in sodium chloride
Injection1 mg/mL, 50 mL vials
ARGATROBAN
12/16/2011
lapatinib ditosylate
Tablets250 mg
TYKERB
3/14/2011
olopatadine hydrochloride
Nasal Spray0.665 mg/ Spray
PATANASE
6/29/2009
travoprost (preserved)
Ophthalmic Solution0.00%
TRAVATAN Z
2/19/2009
olopatadine hydrochloride
Ophthalmic Solution0.20%
PATADAY
9/8/2008
argatroban
Injection100 mg/mL, 2.5 mL vials
ARGATROBAN
9/24/2007
olopatadine hydrochloride
Ophthalmic Solution0.10%
PATANOL
7/17/2006
moxifloxacin hydrochloride
Ophthalmic0.50%
VIGAMOX
12/22/2005
ondansetron hydrochloride
Oral Solution4 mg/5 mL
ZOFRAN
12/20/2004

Non-Orange Book Patents for Novartis Pharms Corp

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,825,116N2, N4-bis-aryl-5-fluoro-2,4-pyrimidinediamines► Subscribe
8,557,806Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds► Subscribe
7,754,733Crystalline topotecan hydrochloride product and process for making the same► Subscribe
6,486,138 Ophthalmic compositions containing galactomannan polymers and borate► Subscribe
8,334,2962,4-pyrimidinediamine compounds and their uses► Subscribe
9,346,7652,4-pyrimidinediamine compounds and their uses► Subscribe
7,858,626Pyrimidineamines as angiogenesis modulators► Subscribe
9,499,4932,4-pyrimidinediamine compounds and their uses► Subscribe
7,812,029Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds► Subscribe
7,557,2102,4-pyrimidinediamine compounds and their uses► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Novartis Pharms Corp Drugs

Country Document Number Estimated Expiration
China104707145► Subscribe
SloveniaEP1343782► Subscribe
Japan5560496► Subscribe
Eurasian Patent Organization025198► Subscribe
Argentina070888► Subscribe
Denmark1534390► Subscribe
Indonesia19609► Subscribe
TaiwanI333492► Subscribe
Japan5202302► Subscribe
Hong Kong1178802► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Novartis Pharms Corp Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00026Denmark► SubscribePRODUCT NAME: PASIREOTID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER ET HVILKET SOM HELST HYDRAT DERAF, HERUNDER PASIREOTIDDIASPARTAT; REG. NO/DATE: EU/1/12/753 20141119
301Luxembourg► SubscribePRODUCT NAME: NEPAFENAC-SUSPENSION OPHTALMIQUE
00536Netherlands► SubscribePRODUCT NAME: PASIREOTIDE, DESGEWENST IN DE VORM VAN EEN ZOUT, IN HET BIJZONDER PASIREOTIDEDI-ASPARTAAT; REGISTRATION NO/DATE: EU/1/12/753/001-012 20120424
2012017Lithuania► SubscribePRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
2010000037Germany► SubscribePRODUCT NAME: ELTROMBOPAG SOWIE PHARMAZEUTISCH ANNEHMBARE SALZE, HYDRATE UND SOLVATE DAVON; NAT. REGISTRATION NO/DATE: EU/1/10/612/001-006 20100311; FIRST REGISTRATION: EU EU/1/10/612/001-/006 20100311
2016000038Germany► SubscribePRODUCT NAME: SACUBITRIL/VALSARTAN, ALS SACUBITRIL VALSARTAN NATRIUM SALZKOMPLEX, D.H. TRINATRIUM-(3-((1 S,3R)-1-BIPHENYL-4-YLMETHYL-3-ETHOXYCARBONYL-1-BUTYLCARBAMOYL)PROPIONAT-(S)-3'-METHYL-2'-(PENTANOYL-(2"-(TETRAZOL-5-YLAT)BIPHENYL-4'-YLMETHYL)AMINO)BUTYRAT)-HEMIPENTAHYDRAT.; REGISTRATION NO/DATE: EU/1/15/1058 20151119
2016 00023Denmark► SubscribePRODUCT NAME: SACUBITRIL/VALSARTAN SOM SACUBITRIL-VALSARTAN-NATRIUMSALTKOMPLEKS; REG. NO/DATE: EU/1/15/1058 (C(2015)8288) 20151123
2010 00024Denmark► Subscribe
C0058France► SubscribePRODUCT NAME: NELARABINE, OU L?UN DE SES DERIVES PHYSIOLOGIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/07/403/001 DU 20070822; REGISTRATION NO/DATE AT EEC: EU/1/07/403/001 DU 20070822
12/033Ireland► SubscribePRODUCT NAME: TRAVOPROST (ALSO CALLED FLUPROSTENOL ISOPROPYL ESTER); NAT REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; FIRST REGISTRATION NO/DATE: EU/1/01/199/001-002 20011129; PAEDIATRIC INVESTIGATION PLAN: P/0298/2013 PROCEEDINGS UNDER SECTION 37 OF THE PATENTS ACT, 1992 RESTORATION ORDER DATED 12TH JANUARY 2016, WAS MADE RESTORING THE PATENT MENTIONED BELOW S85583 PAUL DOYLE A RE-USABLE BAG SYSTEM RESTORATION ORDERS DATED 16TH FEBRUARY 2016, WERE MADE RESTORING THE PATENTS MENTIONED BELOW S86133 MERVYN GREENE MULTI PURPOSE TANK STAND WITH COMPLEX LOCKING MECHANISM 86119 MPC GREEN LIMITED ANEW BIN
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
QuintilesIMS
AstraZeneca
Harvard Business School
Baxter
Citi
Cerilliant
Fish and Richardson
US Army
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot